Redwoods Acquisition Corp. (RWOD)
After hours:
| Previous close | 6.64 |
| Open | 6.63 |
| Bid | 5.96 x 100 |
| Ask | 7.04 x 100 |
| Day's range | 5.79 - 6.72 |
| 52-week range | 4.98 - 13.10 |
| Volume | |
| Avg. volume | 119,843 |
| Market cap | 34.142M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | 48.85 |
| EPS (TTM) | 0.13 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Simply Wall St.Redwoods Acquisition Corp. (NASDAQ:RWOD) surges 16%; retail investors who own 42% shares profited along with insiders
Key Insights Significant control over Redwoods Acquisition by retail investors implies that the general public has more...
PR NewswireANEW MEDICAL ANNOUNCES KEY PATENT ISSUED IN CHINA TO PROTECT KLOTHO PROTEIN AND GENE DELIVERY SYSTEMS
ANEW MEDICAL, INC. ("ANEW" or "the Company") (OTCPK: LEAS) a US-based biotechnology company ("ANEW") focused on developing cell and gene- based treatments to affect aging and age-related diseases, announced that is has been granted and issued a patent in China, number CN 117126829 A for the use of ANEW's Klotho protein and Klotho gene delivery and expression systems in the treatment of cognition, memory and neurodegenerative diseases. This intellectual property was licensed by ANEW from UNIVERSI
PR NewswireANEW MEDICAL, INC. (OTC: LEAS) and Redwoods Acquisition Corp. (NASDAQ: RWOD) Entered into a Definitive Merger Agreement
ANEW MEDICAL, INC. (OTC: LEAS), an early-stage biotechnology company focused on developing disruptive new therapies to treat age-related neurodegenerative diseases, previously announced that it has entered into a definitive business combination agreement with Redwoods Acquisition Corp. (NASDAQ: RWOD; "Redwoods"), a publicly traded special purpose acquisition company, or SPAC. ANEW MEDICAL (ANEW) currently has its common stock quoted on the OTC Markets under the symbol "LEAS".
